Nanostart holding Lumiphore announces European launch of diagnostic tests
Feb 27, 2012
OTC Disclosure News Service
Frankfurt / Richmond, Calif. – Nanostart holding Lumiphore announced the European launch of three diagnostic tests by its partner ThermoFisher Scientific Clinical Diagnostics using Lumiphore’s time-resolved fluorescent reporter technology.
ThermoFisher Clinical Diagnostics has launched three CE-marked in vitro diagnostic tests in countries of the European Economic Area (EEA), consisting of the 27 Member States of the EU and EFTA countries, Iceland, Norway, Switzerland, and Liechtenstein.
The tests are assays produced by Brahms with the designations Copeptin us KRYPTOR, CT-proAVP KRYPTOR, and TRAK human KRYPTOR. Since June 2009, Brahms has been a contractual partner of Lumiphore. The company was acquired by ThermoFisher in September 2009.
These diagnostic tests use Lumiphore’s Lumi4® technology, a new class of fluorescent-metal lanthanide detection reagents patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley.
“Using Lumi4®-Tb will not only potentially increase sensitivity of certain BRAHMS diagnostic tests, but we are hopeful BRAHMS will consider the development of multiplexed assays – measuring 3-4 parameters in one test sample,” explained Dr. Steven Blose, Lumiphore’s chief business officer. The impact of multiplexing – multiple diagnostic tests in one sample – on the daily clinical routine spares patients the burden of repeated blood withdrawal, while simultaneously saving time and expense for hospitals.
Nanostart AG (OTCQX: NASRY) headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government.
Based in Richmond, California, Lumiphore Inc., a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications, which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. For more information about Lumiphore, visit www.lumiphore.com. Lumi4® is a registered mark of Lumiphore, Inc.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
Dr. Hans Joachim Duerr
Head of Corporate Communications
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.